Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Utility of Midodrine During the Recovery Phase of Shock: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Utility of Midodrine During the Recovery Phase of Shock: A Systematic Review and Meta-analysis of... e274 Letters to the Editor pulmonary aspergillosis(1). Emerg Infect Dis. 2021;27: 26. Huang L, Zhang N, Huang X, et al. Invasive pulmonary 2892–2898. aspergillosis in patients with influenza infection: a retro- 20. Kim SH, Hong JY, Bae S, et al. Risk factors for coronavi- spective study and review of the literature. Clin Respir J. rus disease 2019 (COVID-19)-Associated pulmonary 2019;13:202–211. aspergillosis in critically ill patients: a nationwide, mul- 27. Ali ZA, Ali A, Tempest M, et al. Invasive pulmonary ticenter, retrospective cohort study. J Korean Med Sci. aspergillosis complicating chronic obstructive pulmo- 2022;37:e134. nary disease in an immunocompetent patient. 21. Koehler P, Bassetti M, Chakrabarti A, et al. Defining and J Postgrad Med. 2003;49:78–80. managing COVID-19-associated pulmonary aspergillosis: 28. Cicek N, Yildiz N, Kadayifci EK, et al. Invasive aspergil- the 2020 ECMM/ISHAM consensus criteria for research losis in a patient with end stage renal disease. Med Mycol and clinical guidance. Lancet Infect Dis. 2021;21:e149–e162. Case Rep. 2017;18:12–14. 22. Mitaka H, Kuno T, Takagi H, et al. Incidence and mor- 29. Stevens DA, Melikian GL. Aspergillosis in the ‘nonimmu- tality of COVID-19-associated pulmonary aspergillosis: nocompromised’ host. Immunol Invest. 2011;40:751–766. a systematic review and meta-analysis. Mycoses. 2021; 30. Sahlen AO, Suvarna http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Therapeutics Wolters Kluwer Health

Utility of Midodrine During the Recovery Phase of Shock: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Loading next page...
 
/lp/wolters-kluwer-health/utility-of-midodrine-during-the-recovery-phase-of-shock-a-systematic-ZwsTf6s2TW

References (14)

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1075-2765
eISSN
1536-3686
DOI
10.1097/mjt.0000000000001610
Publisher site
See Article on Publisher Site

Abstract

e274 Letters to the Editor pulmonary aspergillosis(1). Emerg Infect Dis. 2021;27: 26. Huang L, Zhang N, Huang X, et al. Invasive pulmonary 2892–2898. aspergillosis in patients with influenza infection: a retro- 20. Kim SH, Hong JY, Bae S, et al. Risk factors for coronavi- spective study and review of the literature. Clin Respir J. rus disease 2019 (COVID-19)-Associated pulmonary 2019;13:202–211. aspergillosis in critically ill patients: a nationwide, mul- 27. Ali ZA, Ali A, Tempest M, et al. Invasive pulmonary ticenter, retrospective cohort study. J Korean Med Sci. aspergillosis complicating chronic obstructive pulmo- 2022;37:e134. nary disease in an immunocompetent patient. 21. Koehler P, Bassetti M, Chakrabarti A, et al. Defining and J Postgrad Med. 2003;49:78–80. managing COVID-19-associated pulmonary aspergillosis: 28. Cicek N, Yildiz N, Kadayifci EK, et al. Invasive aspergil- the 2020 ECMM/ISHAM consensus criteria for research losis in a patient with end stage renal disease. Med Mycol and clinical guidance. Lancet Infect Dis. 2021;21:e149–e162. Case Rep. 2017;18:12–14. 22. Mitaka H, Kuno T, Takagi H, et al. Incidence and mor- 29. Stevens DA, Melikian GL. Aspergillosis in the ‘nonimmu- tality of COVID-19-associated pulmonary aspergillosis: nocompromised’ host. Immunol Invest. 2011;40:751–766. a systematic review and meta-analysis. Mycoses. 2021; 30. Sahlen AO, Suvarna

Journal

American Journal of TherapeuticsWolters Kluwer Health

Published: Feb 28, 2023

There are no references for this article.